Formulary
Raloxifene hydrochloride: Indications, Dosing, Side Effects and Interactions
Raloxifene hydrochloride clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Raloxifene hydrochloride: Indications, Dosing, Side Effects and Interactions
Raloxifene hydrochloride clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**Treatment and prevention of postmenopausal osteoporosis**
- **Adult** (By Mouth): 60 mg once daily.
**Breast cancer [chemoprevention in postmenopausal women at moderate to high risk] (initiated under specialist supervision)**
- **Adult** (By Mouth): 60 mg once daily for 5 years.
Cautions
Avoid in Acute porphyrias ; breast cancer (manufacturer advises avoid during treatment for breast cancer); history of oestrogen-induced hypertriglyceridaemia (monitor serum triglycerides); risk factors for stroke; risk factors for venous thromboembolism (discontinue if prolonged immobilisation)
Contraindications
Cholestasis; endometrial cancer; history of venous thromboembolism; undiagnosed uterine bleeding
Side effects
Common or very common Influenza; leg cramps; peripheral oedema; vasodilation Uncommon Embolism and thrombosis Rare or very rare Breast abnormalities; gastrointestinal discomfort; gastrointestinal disorder; headaches; nausea; rash; thrombocytopenia; vomiting
Interactions
**Other interactions (9):**
- Co-administration of raloxifene and warfarin does not alter the pharmacokinetics of either compound.
- However, modest decreases in the prothrombin time have been observed, and if raloxifene is given concurrently with warfarin or other coumarin derivatives, the prothrombin time should be monitored.
- Raloxifene has no effect on the pharmacokinetics of methylprednisolone given as a single dose.
- Raloxifene does not affect the steady-state AUC of digoxin.
- The C max of digoxin increased by less than 5%.
- Frequently co-administered medicinal products included: paracetamol, non-steroidal anti-inflammatory drugs (such as acetylsalicylic acid, ibuprofen, and naproxen), oral antibiotics, H1-antagonists,...
Hepatic impairment
Manufacturer advises avoid (risk of increased exposure).
Renal impairment
Caution in mild to moderate impairment. M Avoid in severe impairment. M
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Raloxifene hydrochloride in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

